American Heart Journal
Volume 147, Issue 5 , Pages 931-938 , May 2004

Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure

  • Wei-Hsian Yin, MD

      Affiliations

    • Division of Cardiology, Taipei, Taiwan
    • Institute of Clinical Medicine, Taipei, Taiwan
    • Cardiovascular Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Jaw-Wen Chen, MD

      Affiliations

    • Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan
    • Cardiovascular Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Hsu-Lung Jen, MD

      Affiliations

    • Division of Cardiology, Taipei, Taiwan
    • ,
  • Meng-Cheng Chiang, MD

      Affiliations

    • Division of Cardiology, Taipei, Taiwan
    • ,
  • Wen-Pin Huang, MD

      Affiliations

    • Division of Cardiology, Taipei, Taiwan
    • ,
  • An-Ning Feng, MD

      Affiliations

    • Division of Cardiology, Taipei, Taiwan
    • ,
  • Mason Shing Young, MD, FACC

      Affiliations

    • Department of Internal Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan
    • ,
  • Shing-Jong Lin, MD, PhD

      Affiliations

    • Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan
    • Institute of Clinical Medicine, Taipei, Taiwan
    • Cardiovascular Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • Corresponding Author InformationReprint requests: Shing-Jong Lin, MD, PhD, Division of Cardiology, Taipei Veterans General Hospital, 201, Sec 2, Shih-Pai Rd, Taipei 112, Taiwan.

Received 16 May 2003 ,Accepted 17 November 2003.

References 

  1. Seta Y, Shan K, Bozkurt B, et al.  Basic mechanisms in heart failure (the cytokine hypothesis). J Card Fail. 1996;3:243–249
  2. Mann DL. Mechanisms and models in heart failure (a combinatorial approach). Circulation. 1999;100:999–1008
  3. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure (cytokines, nitric oxide, and endothelin-1). Int J Cardiol. 2000;72:175–186
  4. Finkel MS, Oddis CV, Jacob TD, et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–389
  5. Ridker PM, Hennekens CH, Buring JE, et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  6. Mendall MA, Strachan DP, Butland BK, et al.  C-reactive protein (relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men). Eur Heart J. 2000;21:1584–1590
  7. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis (a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease). JAMA. 2001;285:2481–2485
  8. Pye M, Rae AP, Cobbe SM. Study of serum C-reactive protein concentration in cardiac failure. Br Heart J. 1990;63:228–230
  9. Kaneko K, Kanda T, Yamauchi Y, et al.  C-reactive protein in dilated cardiomyopathy. Cardiology. 1999;91:215–219
  10. Sato Y, Takatsu Y, Kataoka K, et al.  Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 1999;22:811–813
  11. Pietila KO, Harmoinen AP, Jokiniitty J, et al.  Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345–1349
  12. Steele IC, Maguire NS, Campbell HG, et al.  Cytokine profile in chronic cardiac failure. Eur J Clin Invest. 1996;26:1018–1022
  13. Gottdiener JS, Arnold AM, Aurigemma GP, et al.  Predictors of congestive heart failure in the elderly (the cardiovascular health study). J Am Coll Cardiol. 2000;35:1628–1637
  14. Ridker PM. High-sensitivity C-reactive protein (potential adjunct for global risk assessment in the primary prevention of cardiovascular disease). Circulation. 2001;103:1813–1818
  15. Roberts WL, Moulton L, Law TC, et al.  Evaluation of nine automated high sensitivity C-reactive protein methods (implications for clinical and epidemiological applications). Clin Chem. 2001;47:418–425
  16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454
  17. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406–418
  18. Yamauchi-Takihara K, Ihara Y, Ogata A, et al.  Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520–1524
  19. Clark DJ, Cleman MW, Pfau SE, et al.  Serum complement activation in congestive heart failure. Am Heart J. 2001;141:684–690
  20. Fava RA, Gates C, Townes AS. Critical role of peripheral blood phagocytes and the involvement of complement in tumor necrosis factor enhancement of passive collagen-arthritis. Clin Exp Immunol. 1993;94:261–266
  21. Hsueh W, Sun X, Rioja LN, et al.  The role of the complement system in shock and tissue injury induced by tumor necrosis factor and endotoxin. Immunology. 1990;70:309–314
  22. Verma S, Wang CH, Li SH, et al.  A self-fulfilling prophecy (C-reactive protein attenuates nitric oxide production and inhibits angiogenesis). Circulation. 2002;106:913–919
  23. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4:361–368
  24. Cermak J, Key NS, Bach RR, et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513–520
  25. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  26. Yin WH, Chen JW, Jen HL, et al.  The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 2003;5:507–516
  27. Tsutamoto T, Wada A, Maeda K, et al.  Angiotensin II type I receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000;35:714–721
  28. Drexler H, Kurz S, Jeserich M, et al.  Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J of Cardiol. 1995;76:13; –8E
  29. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546–549
  30. Remme WJ. Prevention of worsening heart failure (future focus). Eur Heart J. 1998;19(Suppl B):B47–53

PII: S0002-8703(03)00859-7

doi: 10.1016/j.ahj.2003.11.021

American Heart Journal
Volume 147, Issue 5 , Pages 931-938 , May 2004

Article Tools

* Image Usage & Resolution